Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 1
2006 1
2007 1
2008 3
2009 3
2010 1
2011 1
2012 4
2013 1
2014 3
2015 5
2016 3
2017 4
2018 6
2019 1
2020 4
2021 5
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean jerome clusters (222 results)?
Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.
van der Neut Kolfschoten M, Inganäs H, Perez-Peinado C, Calado da Silva Freire J, Melchers JM, van Dijk N, Przeradzka M, Kourkouta E, van Manen D, Vellinga J, Custers J, Bos R. van der Neut Kolfschoten M, et al. Among authors: custers j. J Thromb Haemost. 2024 Apr;22(4):1046-1055. doi: 10.1016/j.jtha.2023.12.020. Epub 2023 Dec 29. J Thromb Haemost. 2024. PMID: 38159648 Free article.
Risk of COVID-19 after natural infection or vaccination.
Rick AM, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, Rostad CA, Maboa RM, Baden LR, El Sahly HM, Grinsztejn B, Gray GE, Gay CL, Gilbert PB, Janes HE, Kublin JG, Huang Y, Leav B, Hirsch I, Struyf F, Dunkle LM, Neuzil KM, Corey L, Goepfert PA, Walsh SR, Follmann D, Kotloff KL; NIAID-funded COVID-19 Prevention Network (CoVPN). Rick AM, et al. EBioMedicine. 2023 Oct;96:104799. doi: 10.1016/j.ebiom.2023.104799. Epub 2023 Sep 20. EBioMedicine. 2023. PMID: 37738833 Free PMC article. Clinical Trial.
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, Leav B, Miller J, Hirsch I, Sadoff J, Dunkle LM, Neuzil KM, Corey L, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y; COVID-19 Prevention Network (CoVPN). Theodore DA, et al. JAMA Netw Open. 2023 Jul 3;6(7):e2323349. doi: 10.1001/jamanetworkopen.2023.23349. JAMA Netw Open. 2023. PMID: 37440227 Free PMC article.
Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.
Swart M, van der Lubbe J, Schmit-Tillemans S, van Huizen E, Verspuij J, Gil AI, Choi Y, Daal C, Perkasa A, de Wilde A, Claassen E, de Jong R, Wiese KE, Cornelissen L, van Es M, van Heerden M, Kourkouta E, Tahiri I, Mulders M, Vreugdenhil J, Feddes-de Boer K, Muchene L, Tolboom J, Dekking L, Juraszek J, Vellinga J, Custers J, Bos R, Schuitemaker H, Wegmann F, Roozendaal R, Kuipers H, Zahn R. Swart M, et al. Among authors: custers j. NPJ Vaccines. 2023 Mar 16;8(1):40. doi: 10.1038/s41541-023-00633-x. NPJ Vaccines. 2023. PMID: 36927774 Free PMC article.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Hardt K, et al. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Lancet Infect Dis. 2022. PMID: 36113538 Free PMC article. Clinical Trial.
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, Treanor J, Ryser MF, Barouch DH, Swann E, Marovich MA, Neuzil KM, Corey L, Stoddard J, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Sadoff J, et al. Among authors: custers j. N Engl J Med. 2022 Mar 3;386(9):847-860. doi: 10.1056/NEJMoa2117608. Epub 2022 Feb 9. N Engl J Med. 2022. PMID: 35139271 Free PMC article. Clinical Trial.
Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development.
Ballmann MZ, Raus S, Engelhart R, Kaján GL, Beqqali A, Hadoke PWF, van der Zalm C, Papp T, John L, Khan S, Boedhoe S, Danskog K, Frängsmyr L, Custers J, Bakker WAM, van der Schaar HM, Arnberg N, Lemckert AAC, Havenga M, Baker AH. Ballmann MZ, et al. Among authors: custers j. J Virol. 2021 Oct 27;95(22):e0038721. doi: 10.1128/JVI.00387-21. Epub 2021 Sep 1. J Virol. 2021. PMID: 34469243 Free PMC article.
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
Solforosi L, Kuipers H, Jongeneelen M, Rosendahl Huber SK, van der Lubbe JEM, Dekking L, Czapska-Casey DN, Izquierdo Gil A, Baert MRM, Drijver J, Vaneman J, van Huizen E, Choi Y, Vreugdenhil J, Kroos S, de Wilde AH, Kourkouta E, Custers J, van der Vlugt R, Veldman D, Huizingh J, Kaszas K, Dalebout TJ, Myeni SK, Kikkert M, Snijder EJ, Barouch DH, Böszörményi KP, Stammes MA, Kondova I, Verschoor EJ, Verstrepen BE, Koopman G, Mooij P, Bogers WMJM, van Heerden M, Muchene L, Tolboom JTBM, Roozendaal R, Brandenburg B, Schuitemaker H, Wegmann F, Zahn RC. Solforosi L, et al. Among authors: custers j. J Exp Med. 2021 Jul 5;218(7):e20202756. doi: 10.1084/jem.20202756. J Exp Med. 2021. PMID: 33909009 Free PMC article.
54 results